Skip to main content

RMD

Stock

RMD

Stock
Health Care
Medical Instruments & Supplies

Performance overview

RMD Price
Price Chart

Forward-looking statistics

Beta
0.62
Risk
33.13%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

at resmed (nyse: rmd, asx: rmd) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. our cloud-connected medical devices transform care for people with sleep apnea, copd and other chronic diseases. our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. by enabling better care, we improve quality of life, reduce the impact of chronic disease and lower costs for consumers and healthcare systems in more than 120 countries.

Company info

SectorHealth Care
IndustryMedical Instruments & Supplies
Employees8K
Market cap$31.0B

Fundamentals

Enterprise value$37.7B
Revenue$5.0B
Revenue per employee—
Profit margin26.15%
Debt to equity15.14

Security info

ExchangeNyse American
Type of shareCommon Stock
Earnings per share (EPS)$8.92
Dividend per share$2.12
Revenue per share$34.20
Avg trading volume (30 day)$195M
Avg trading volume (10 day)$228M
Put-call ratio—

Macro factor sensitivity

Growth-0.9
Credit+3.1
Liquidity+0.6
Inflation-4.4
Commodities-0.0
Interest Rates-0.7

Valuation

Dividend yield0.82%
PEG Ratio24.97
Price to sales7.50
P/E Ratio24.97
Enterprise Value to Revenue7.51
Price to book6.79

Upcoming events

Next earnings dayApril 24, 2025
Next dividend day—
Ex. dividend dayMay 8, 2025

News

Is TORM (TRMD) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Investment Research (July 8, 2025)
CorMedix Analyst Says Investors Could Be Further Rewarded

Last week, CorMedix Inc. CRMD said one of its large dialysis organization (LDO) customers has started ordering, with implementation planned for the second half of 2025.

Benzinga (June 30, 2025)
Concentrix Posts Downbeat Earnings, Joins CorMedix And Other Big Stocks Moving Lower In Friday's Pre-Market Session

U.S. stock futures were higher this morning, with the Dow futures gaining over 100 points on Friday.

Benzinga (June 27, 2025)
All You Need to Know About ResMed (RMD) Rating Upgrade to Buy

ResMed (RMD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research (June 25, 2025)
Strength Seen in CorMedix (CRMD): Can Its 21.7% Jump Turn into More Strength?

CorMedix (CRMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Investment Research (June 24, 2025)
ResMed Boasts Double-Digit EPS Growth, Tariff Exemption: Analysts Boost Price Forecast

On Wednesday, ResMed Inc RMD reported that third-quarter adjusted EPS was $2.37, beating the consensus of $2.36.

Benzinga (April 24, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free